CD274 and osteosarcoma: We observed no significant difference in the survival of metastatic osteosarcoma implanted mice when treated for 30 days vs 15 days; mice receiving α-PD-L1 mAb therapy perished from pulmonary metastases with a median survival of 68 days in both groups (Figure 1A).